Monopar says Phase 3 trial shows ALXN1840 beats standard care on neurologic Wilson disease outcomes

• Monopar presented new Phase 3 FoCus trial analyses at AAN 2026 showing ALXN1840 delivered greater neurologic benefit than standard of care in Wilson disease patients with neurologic symptoms at baseline.
• Results indicated more patients improved while fewer deteriorated on ALXN1840 versus standard treatments through Week 48.
• Long-term follow-up suggested neurologic gains on ALXN1840 were sustained over about 3 years.
• Safety profile remained favorable across Phase 2 and Phase 3 experience, supporting planned mid-2026 FDA NDA submission.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-012751), on April 20, 2026, and is solely responsible for the information contained therein.